SeraNovo

Solving the insoluble

Pharmaceutical companies have one major problem, poor bioavailability stops drugs getting to the market. Solving this problem takes a long time, costs a lot of money and reduces highly profitable patent life. This is a €9.2 billion market.

SeraNovo’s proprietary formulation platform radically increases bioavailability and allows products to reach the market significantly quicker, at a lower cost.

For every drug, SeraNovo creates a purpose designed eutectic mixture and couples it with polymers to create a formulation. When orally administered these formulations create a supersaturated state in the intestine resulting in a significantly higher bioavailability.

SeraNovo is seeking an investment of €600,000 to validate the technology and establish the first two licence agreements. In year 5 SeraNovo will have established 14 licence agreements with major pharmaceutical companies. Successful licence agreements will lead to a % of net sales when the licensee’s drug reaches the market

 

Team
Niall Hodgins
Bastiaan Kluft
Ian Degeling
Startup activities

Winner Venture Challenge Fall 2018

SeraNovo Winner Venture Challenge Fall 2018

Contact
Niall Hodgins
info@seranovo.com